Neurol. praxi. 2026;27(3):181-185 | DOI: 10.36290/neu.2026.022

Botulinum toxin treatment of oromandibular and laryngeal dystonia

MUDr. Monika Turčanová Kopruąáková, PhD.1, MUDr. Jozef Haring, PhD.2, MUDr. Ján Necpál, PhD.3, 4, 5
1 Neurologická klinika Jesseniova lekárska fakulta a Univerzitná nemocnica Martin
2 Neurologická klinika, Fakultná nemocnica Trnava
3 Neurologické oddelenie, Nemocnica Zvolen, a. s.
4 Centrum pre liečbu parkinsonizmu a extrapyramídových porúch, Nemocnica Zvolen, a. s.
5 Neurologická klinika, Univerzita Pavla Jozefa ©afárika, Koąice

Oromandibular and laryngeal dystonia are relatively rare focal dystonia with diverse etiology and clinical presentation. Although botulinum toxin treatment is considered off-label in both, empirical experience points to its effect and justification in clinical practice. Adequate erudition in application, often with the need for EMG navigation, and multidisciplinary patient care in both types of diseases increase the likelihood of symptomatic improvement of their condition.

Keywords: laryngeal dystonia, spasmodic dysphonia, oromandibular dystonia, botulinum toxin.

Received: January 22, 2026; Revised: March 20, 2026; Accepted: April 11, 2026; Prepublished online: April 11, 2026; Published: July 20, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Turčanová Kopruąáková M, Haring J, Necpál J. Botulinum toxin treatment of oromandibular and laryngeal dystonia. Neurol. praxi. 2026;27(3):181-185. doi: 10.36290/neu.2026.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 20.7.2027

    References

    1. Ameer MA, Bhatti D. Chemodenervation for Oromandibular Dystonia Utilizing Botulinum Toxins. Cureus. 2021;13:e18425. Go to original source...
    2. Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol. 2006;13:21-9. Go to original source...
    3. Bhidayasiri R, Maytharakcheep S, Truong DD. Patient selection and injection techniques for botulinum neurotoxin in oromandibular dystonia. Clin Park Relat Disord. 2022;7:100160. Go to original source...
    4. Blitzer A, Benson BE, Kirke DN. Botulinum Neurotoxin for Head and Neck Disorders. 2. Auflage. Thieme Medical Publishers. 2020. Go to original source...
    5. Blitzer A, Brin MF, Simonyan K, et al. Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30-year experience. The Laryngoscope. 2018;128(S1). Go to original source...
    6. Fasano A, Valadas A, Bhatia KP, et al. Psychogenic facial movement disorders: Clinical features and associated conditions. Mov Disord. 2012;27:1544-51. Go to original source...
    7. Hassell TJW, Charles D. Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins. Toxins (Basel). 2020;12:269. Go to original source...
    8. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:35-62. Go to original source...
    9. Jankovic J, Hallett M, Okun MS, et al. Principles and Practice of Movement Disorders. Third edition. (eds.). Elsevier. 2022. Go to original source...
    10. Jinnah HA. Medical and Surgical Treatments for Dystonia. Neurol Clin. 2020;38:325-48. Go to original source...
    11. Ludlow CL, Naunton RF, Fujita M, et al. Spasmodic Dysphonia: Botulinum Toxin Injection after Recurrent Nerve Surgery. Otolaryngol Head Neck Surg. 1990;102:122-131. Go to original source...
    12. Martino D, Berardelli A, Abbruzzese G, et al. Age at onset and symptomspread in primary adult-onset blepharospasm and cervical dystonia. Mov Disord. 2012;27:1447-50. Go to original source...
    13. Mendes RA, Upton LG. Management of dystonia of the lateral pterygoid muscle with botulinum toxin A. Br J Oral Maxillofac Surg. 2009;47:481-3. Go to original source...
    14. Patel AB, Bansberg SF, Adler CH, et al. The Mayo Clinic Arizona Spasmodic Dysphonia Experience: A Demographic Analysis of 718 Patients. Ann Otol Rhinol Laryngol. 2015;124:859-863. Go to original source...
    15. Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: A 20-year follow-up. Toxicon .2014;90:344-8. Go to original source...
    16. Saraf U, Chandarana M, Divya KP, et al. Oromandibular Dystonia - a Systematic Review. Ann Indian Acad Neurol. 2022;25:26-34. Go to original source...
    17. Shrivastava M, Ye L. Oromandibular dystonia and temporomandibular disorders-a review on diagnosis and management. J Oral Maxillofac Anesth. 2024;3:13. Go to original source...
    18. Slaim L, Cohen M, Klap P, et al. Oromandibular dystonia: Demographics and clinical data from 240 patients. J Mov Disord. 2018;11:78-81. Go to original source...
    19. Spasmodic dysphonia (SD, Laryngeal dystonia) [online] [cit. 19.1.2026]. Dostupné na: https://laryngopedia.com/spasmodic-dysphonia/.
    20. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up. Neurology. 1999;53:2102-7. Go to original source...
    21. Yoshida K. Botulinum Neurotoxin Therapy for Lingual Dystonia Using an Individualized Injection Method Based on Clinical Features. Toxins (Basel). 2019;11:51. Go to original source...
    22. Yeung W, Richards AL, Novakovic D. Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia. Toxins. 2022;14:844. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.